Published in J Biol Chem on March 15, 2006
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One (2009) 1.05
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids. Cell Cycle (2014) 0.96
Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J (2007) 0.96
Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis (2011) 0.92
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J Biol Chem (2013) 0.90
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells. Oncoscience (2014) 0.89
In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis (2012) 0.85
The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol (2011) 0.81
Exogenous ether lipids predominantly target mitochondria. PLoS One (2012) 0.81
Lipid analogues as potential drugs for the regulation of mitochondrial cell death. Br J Pharmacol (2014) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood (2004) 2.61
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood (2006) 1.49
Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med (2004) 1.46
The metalloprotease ADAM8 is associated with and regulates the function of the adhesion receptor PSGL-1 through ERM proteins. Eur J Immunol (2011) 1.45
Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat (2006) 1.25
Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab (2002) 1.17
Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem (2005) 1.16
Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils. J Immunol (2006) 1.16
Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem (2002) 1.15
Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J Biol Chem (2005) 1.12
Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol (2007) 1.11
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res (2007) 1.06
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One (2009) 1.05
ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem (2004) 1.01
In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res (2010) 1.00
Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism. Clin Cancer Res (2003) 0.99
Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun (2009) 0.98
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids. Cell Cycle (2014) 0.96
Rapid human melanoma cell death induced by sanguinarine through oxidative stress. Eur J Pharmacol (2013) 0.95
DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol (2005) 0.94
Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. Anticancer Agents Med Chem (2014) 0.93
Rab27a regulates exocytosis of tertiary and specific granules in human neutrophils. J Immunol (2008) 0.91
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J Biol Chem (2013) 0.90
Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B (2008) 0.89
Lipid rafts and Fas/CD95 signaling in cancer chemotherapy. Recent Pat Anticancer Drug Discov (2011) 0.89
Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol (2010) 0.88
Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety. J Med Chem (2005) 0.86
Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine). Biochim Biophys Acta (2007) 0.86
In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis (2012) 0.85
Expression and subcellular localization of syntaxin 11 in human neutrophils. Inflamm Res (2009) 0.84
Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin. J Med Chem (2004) 0.84
Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes. Autophagy (2012) 0.84
Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther (2009) 0.84
Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells. Acta Pharmacol Sin (2007) 0.83
Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis. BMC Syst Biol (2010) 0.83
Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur J Pharm Biopharm (2007) 0.83
Alteration of plasma membrane organization by an anticancer lysophosphatidylcholine analogue induces intracellular acidification and internalization of plasma membrane transporters in yeast. J Biol Chem (2013) 0.83
Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells. Anticancer Drugs (2011) 0.82
Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J Chem Biol (2008) 0.82
Synthesis and biological evaluation of new podophyllic aldehyde derivatives with cytotoxic and apoptosis-inducing activities. J Med Chem (2010) 0.82
Cytotoxic oxasqualenoids from the red alga Laurencia viridis. Eur J Med Chem (2011) 0.81
Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes. Int J Pharm (2006) 0.81
Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res (2009) 0.81
Edelfosine induces an apoptotic process in Leishmania infantum that is regulated by the ectopic expression of Bcl-XL and Hrk. Antimicrob Agents Chemother (2008) 0.80
Lipid rafts, death receptors and CASMERs: new insights for cancer therapy. Future Oncol (2010) 0.80
Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem (2004) 0.80
Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol (2009) 0.80
Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling. Apoptosis (2015) 0.79
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds. Bioorg Med Chem (2009) 0.79
Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (Lond) (2012) 0.78
A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKC alpha and PKC epsilon. Biochim Biophys Acta (2005) 0.78
Ipilimumab and vemurafenib: two different routes for targeting melanoma. Curr Cancer Drug Targets (2013) 0.78
In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release (2011) 0.78
New polyether triterpenoids from Laurencia viridis and their biological evaluation. Mar Drugs (2011) 0.77
Human initiator caspases trigger apoptotic and autophagic phenotypes in Saccharomyces cerevisiae. Biochim Biophys Acta (2009) 0.77
Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition. Mitochondrion (2012) 0.77
Synthesis and cytotoxic activity of a new potential DNA bisintercalator: 1,4-Bis{3-[N-(4-chlorobenzo[g]phthalazin-1-yl)aminopropyl]}piperazine. Bioorg Med Chem (2010) 0.77
Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins. J Med Chem (2013) 0.76
Cloning and genomic characterization of sytdep, a new synaptotagmin XIV-related gene. Biochem Biophys Res Commun (2005) 0.76
Intracellular location of syntaxin 7 in human neutrophils. Immunol Lett (2010) 0.76
Plasma nitrate/nitrite (NOx) is not a useful biomarker to predict inherent cardiopulmonary bypass inflammatory response. J Card Surg (2009) 0.75
Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids. J Phys Chem B (2013) 0.75
Triggers and signaling cross-talk controlling cell death commitment. Cell Cycle (2015) 0.75
Lignopurines: a new family of hybrids between cyclolignans and purines. Synthesis and biological evaluation. Eur J Med Chem (2012) 0.75
The plasma membrane: a catalyst in the decision to die or not to die? Recent Pat Anticancer Drug Discov (2011) 0.75
Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.75
Synthesis and evaluation as antitumor agents of 1,4-naphthohydroquinone derivatives conjugated with amino acids and purines. Arch Pharm (Weinheim) (2013) 0.75
Arginase activity and CD3ζ expression after major surgery. Intensive Care Med (2015) 0.75
Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett (2013) 0.75
Synthesis of an ent-halimanolide from ent-halimic acid. Molecules (2008) 0.75
Antitumor activity of new enantiopure pybox-ruthenium complexes. Dalton Trans (2013) 0.75
Antitumor activity of new hydridotris(pyrazolyl)borate ruthenium(II) complexes containing the phosphanes PTA and 1-CH3-PTA. Dalton Trans (2010) 0.75